Home LiteratureArticle Details
PMID: 19442052 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Overcoming drug resistance by enhancing apoptosis of tumor cells.

Current cancer drug targets ·Vol. 9 ·No. 3 ·2009-05-00 ·Pages 320-40

Giménez-Bonafé P, Tortosa A, Pérez-Tomás R

Abstract

Drug resistance remains a major clinical challenge for cancer treatment. One mechanism by which tumor cells develop resistance to cytotoxic agents and radiation is related to resistance to apoptosis. Apoptosis is a well-organised process of cell death pre-programmed inside the cell. Apoptosis can be initiated either by activation of death receptors on the cell surface membranes (extrinsic pathway) or through a series of cellular events primarily processed at mitochondria (intrinsic pathway). Apoptosis has been shown to be important for tumorigenesis and cancer treatment. Defects in apoptosis can result in the expansion of a population of neoplastic cells. However, because the death of tumor cells induced by chemotherapy and radiotherapy is largely mediated by activation of apoptosis, inhibition of apoptosis will make tumor cells resistant to anti-tumor treatment. Herein, we will review the molecular changes that have the potential to cause apoptotic dysregulation, including activation of antiapoptotic factors (Bcl-2, BCLX(L), Bfl1/A1 etc.), inactivation of pro-apoptotic effectors (p53, p53 pathway), and /or reinforcement of survival signals (Survivin, FLIP, NF-kappaB etc). Furthermore, we will discuss therapeutic intervention and/or strategies that can lower the threshold for apoptosis of tumor cells that could became useful approaches to treat cancer with special emphasis placed on the important priority to develop new cancer therapeutics toward tumor stem cells.

MeSH Terms
Antineoplastic Agents/pharmacology,therapeutic use Apoptosis/drug effects,physiology Clinical Trials as Topic Drug Resistance, Neoplasm/drug effects,physiology Humans Neoplasms/drug therapy Perforin/physiology Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors Receptors, Death Domain/drug effects,physiology Receptors, TNF-Related Apoptosis-Inducing Ligand/drug effects,physiology Tumor Necrosis Factor-alpha/drug effects,physiology Tumor Suppressor Protein p53/drug effects,physiology X-Linked Inhibitor of Apoptosis Protein/drug effects,physiology
Chemicals
Antineoplastic Agents Proto-Oncogene Proteins c-bcl-2 Receptors, Death Domain Receptors, TNF-Related Apoptosis-Inducing Ligand Tumor Necrosis Factor-alpha Tumor Suppressor Protein p53 X-Linked Inhibitor of Apoptosis Protein Perforin
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Giménez-Bonafé Pepita
Departament de Ciències Fisiològiques II, Campus Ciènces de Salut de Bellvitge, IDIBELL, University of Barcelona, Barcelona, Spain.
Tortosa Avelina
Pérez-Tomás Ricardo
Article Info
Journal
Current cancer drug targets
Abbr.
Curr Cancer Drug Targets
ISSN
1873-5576
Published
2009-05-00
Pages
320-40
Language
English
Region
Netherlands
NLM ID
101094211
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com